Detaillierte Beitrags-Information

Zurück zur Liste

Beitragstitel Functional voice changes considering age and time to treatment in patients with unilateral vocal fold motion impairment treated with injection laryngoplasty and speech therapy
Beitragscode O25
  1. Silvan Marti Universitätsspital Zürich Präsentierende:r
  2. Jörg Bohlender Abtlg. Phoniatrie und Klinische Logopädie, ORL Universitätsspital Zürich
  3. Meike Brockmann - Bauser USZ Zürich
Präsentationsform Vortrag
  • SGORL FV 2019
Abstract-Text Injection laryngoplasty is widely applied in patients with unilateral vocal fold motion impairment (UVFMI). We investigated functional voice changes and age effects in patients treated with voice therapy alone and combined with injection laryngoplasty.

25 patients (21 men, 4 women) with UVMI of 61 years (37-82) of age were retrospectively assessed before and after treatment at the University Hospital Zurich. 17 patients received injection laryngoplasty combined with speech therapy (group 1) and 8 patients speech therapy alone (group 2). Outcomes were perceptual analysis by Grading-Roughness-Breathiness-Asthenia-Strain (GRBAS) scale, acoustic voice range profiles (VRP), and the Dysphonia Severity Index (DSI). Treatment effects were assessed by Paired t-test and Wilcoxon-signed-rank test, and age effects by Spearman’s rank correlation.

After treatment, in both groups mean GRBAS scale G was significantly improved (p < .05). Mean speaking loudness significantly increased in group 1 from 62 (SD 3.5) to 64 (SD 4.3) and in group 2 from 63 (SD 4.4) to 65 (SD 4.7) dB(A). Also, the DSI significantly improved from -9.1 (SD 13.5) to -0.6 (SD 2.3) in group 1, and from -11.1 (SD 19.4) to -3.2 (SD 11.9) in group 2 (p < .05). Further, in group 1 maximum calling and singing SPL and calling fundamental frequency (F0) significantly increased, and age significantly affected minimum speaking F0 (coefficient: 0.53) in all patients (p < 0.05).

Mean speaking loudness, the DSI and perceptual dysphonia improved in both groups, and thus may be early applicable clinical outcome measures. Age and treatment may affect more voice characteristics, which should be confirmed in a larger clinical study.